ADIL Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat NanoViricides, Inc.'s return on equity of -92.29%.

Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 800.9%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that Adial Pharmaceuticals, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Adial Pharmaceuticals, Inc. is more attractive than NanoViricides, Inc..

Adial Pharmaceuticals, Inc. has a beta of 1.108, which suggesting that the stock is 10.833% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Oragenics, Inc.'s return on equity of -509.23%.

Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 800.9%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that Adial Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe Adial Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..

Adial Pharmaceuticals, Inc. has a beta of 1.108, which suggesting that the stock is 10.833% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Palatin Technologies's return on equity of --.

Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 800.9%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Adial Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Adial Pharmaceuticals, Inc..

Adial Pharmaceuticals, Inc. has a beta of 1.108, which suggesting that the stock is 10.833% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Adial Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Palatin Technologies's net income of --. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 800.9%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Theriva Biologics, Inc. has higher upside potential than Adial Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Adial Pharmaceuticals, Inc..

Adial Pharmaceuticals, Inc. has a beta of 1.108, which suggesting that the stock is 10.833% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.